{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:10:23Z","timestamp":1776280223397,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Cardiac amyloidosis (CA) constitutes an important etiology of heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF). Since patients with CA show early exhaustion, we aimed to investigate whether non-exertional variables of cardiopulmonary exercise testing (CPET) provide additional information in comparison to traditional peak oxygen consumption (VO<jats:sub>2peak<\/jats:sub>).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>We retrospectively investigated CPET variables of patients with HFpEF and HFmrEF with (<jats:italic>n<\/jats:italic>\u2009=\u200921) and without (<jats:italic>n<\/jats:italic>\u2009=\u200921, HF) CA at comparable age and ejection fraction. Exertional and non-exertional CPET variables as well as laboratory and echocardiographic markers were analyzed. The primary outcome was the difference in CPET variables between groups. The secondary outcome was rehospitalization in patients with CA during a follow-up of 24\u00a0months. Correlations between CPET, NTproBNP, and echocardiographic variables were calculated to detect patterns of discrimination between the groups. HF patients with CA were inferior to controls in most exertional and non-exertional CPET variables. Patients with CA were hospitalized more often (<jats:italic>p<\/jats:italic>\u2009=\u20090.002), and rehospitalization was associated with VE\/VCO<jats:sub>2<\/jats:sub> (<jats:italic>p<\/jats:italic>\u2009=\u20090.019), peak oxygen pulse (<jats:italic>p<\/jats:italic>\u2009=\u20090.042), the oxygen equivalent at the first ventilatory threshold (<jats:italic>p<\/jats:italic>\u2009=\u20090.003), circulatory (<jats:italic>p<\/jats:italic>\u2009=\u20090.024), and ventilatory power (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), but not VO<jats:sub>2peak<\/jats:sub> (<jats:italic>p<\/jats:italic>\u2009=\u20090.127). Higher performance was correlated with lower E\/e\u2019 and NTproBNP as well as higher resting heart rate and stroke volume in CA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Patients with CA displayed worse non-exertional CPET performance compared to non-CA HF patients, which was associated with rehospitalization. Differences between correlations of resting echocardiography and CPET variables between groups emphasize different properties of exercise physiology despite comparable ejection fraction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11897-024-00661-1","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T07:01:56Z","timestamp":1713423716000},"page":"224-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["(Non)-Exertional Variables of Cardiopulmonary Exercise Testing in Heart Failure with and Without Cardiac Amyloidosis"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-0939","authenticated-orcid":false,"given":"Simon","family":"Wernhart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Carpinteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Luedike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"issue":"3","key":"661_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","volume":"29","author":"Y Ando","year":"2022","unstructured":"Ando Y, Adams D, Benson MD, Berk JL, Plant\u00e9-Bordeneuve V, Coelho T, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143\u201355. https:\/\/doi.org\/10.1080\/13506129.2022.2052838.","journal-title":"Amyloid"},{"issue":"2","key":"661_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ejhf.1364","volume":"21","author":"S Paolillo","year":"2019","unstructured":"Paolillo S, Veglia F, Salvioni E, Corr\u00e0 U, Piepoli M, Lagioia R, et al. Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. Eur J Heart Fail. 2019;21(2):208\u201317. https:\/\/doi.org\/10.1002\/ejhf.1364. (This work illustrates the prognostic role of peak oxygen consumption and ventilatory efficiency in heart failure to assess hospitalization and cardiovascular death.).","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"661_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/ejhf.2016","volume":"23","author":"M Nicol","year":"2021","unstructured":"Nicol M, Deney A, Lairez O, Vergaro G, Emdin M, Carecci A, et al. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. Eur J Heart Fail. 2021;23(2):231\u20139. https:\/\/doi.org\/10.1002\/ejhf.2016. (The work illustrates the prognostic role of peak oxygen consumption and circulatory power in cardiac amyloidosis, which are tools to assess the risk of hospitalization and mortality.).","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"661_CR4","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/ehf2.14406","volume":"10","author":"A Cantone","year":"2023","unstructured":"Cantone A, Serenelli M, Sanguettoli F, Maio D, Fabbri G, Dal Passo B, et al. Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy: a systematic review and meta-analysis. ESC Heart Fail. 2023;10(4):2740\u20134. https:\/\/doi.org\/10.1002\/ehf2.14406.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"661_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jchf.2020.11.008","volume":"9","author":"A Lala","year":"2021","unstructured":"Lala A, Shah KB, Lanfear DE, Thibodeau JT, Palardy M, Ambardekar AV, et al. Predictive value of cardiopulmonary exercise testing parameters in ambulatory advanced heart failure. JACC Heart Fail. 2021;9(3):226\u201336. https:\/\/doi.org\/10.1016\/j.jchf.2020.11.008.","journal-title":"JACC Heart Fail"},{"issue":"5","key":"661_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1161\/circheartfailure.112.968529","volume":"5","author":"DE Forman","year":"2012","unstructured":"Forman DE, Guazzi M, Myers J, Chase P, Bensimhon D, Cahalin LP, et al. Ventilatory power: a novel index that enhances prognostic assessment of patients with heart failure. Circ Heart Fail. 2012;5(5):621\u20136. https:\/\/doi.org\/10.1161\/circheartfailure.112.968529.","journal-title":"Circ Heart Fail"},{"issue":"16","key":"661_CR7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072.","journal-title":"Eur Heart J"},{"issue":"1","key":"661_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/eurjpc\/zwab007","volume":"29","author":"D Hansen","year":"2022","unstructured":"Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022;29(1):230\u201345. https:\/\/doi.org\/10.1093\/eurjpc\/zwab007.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"661_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/2047487312460484","volume":"20","author":"A Mezzani","year":"2013","unstructured":"Mezzani A, Hamm LF, Jones AM, McBride PE, Moholdt T, Stone JA, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol. 2013;20(3):442\u201367. https:\/\/doi.org\/10.1177\/2047487312460484.","journal-title":"Eur J Prev Cardiol"},{"issue":"36","key":"661_CR10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"37","key":"661_CR11","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"2 Pt 2","key":"661_CR12","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1164\/arrd.1984.129.2P2.S49","volume":"129","author":"JE Hansen","year":"1984","unstructured":"Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. Am Rev Respir Dis. 1984;129(2 Pt 2):S49-55. https:\/\/doi.org\/10.1164\/arrd.1984.129.2P2.S49.","journal-title":"Am Rev Respir Dis"},{"issue":"8","key":"661_CR13","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/0002-9149(87)91116-7","volume":"59","author":"CB Kremser","year":"1987","unstructured":"Kremser CB, O\u2019Toole MF, Leff AR. Oscillatory hyperventilation in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy or to ischemic cardiomyopathy. Am J Cardiol. 1987;59(8):900\u20135. https:\/\/doi.org\/10.1016\/0002-9149(87)91116-7.","journal-title":"Am J Cardiol"},{"issue":"7","key":"661_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/2047487318761679","volume":"25","author":"JA Laukkanen","year":"2018","unstructured":"Laukkanen JA, Ara\u00fajo CGS, Kurl S, Khan H, Jae SY, Guazzi M, et al. Relative peak exercise oxygen pulse is related to sudden cardiac death, cardiovascular and all-cause mortality in middle-aged men. Eur J Prev Cardiol. 2018;25(7):772\u201382. https:\/\/doi.org\/10.1177\/2047487318761679.","journal-title":"Eur J Prev Cardiol"},{"issue":"14","key":"661_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/eurheartj\/ehw180","volume":"39","author":"M Guazzi","year":"2018","unstructured":"Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J. 2018;39(14):1144\u201361. https:\/\/doi.org\/10.1093\/eurheartj\/ehw180.","journal-title":"Eur Heart J"},{"key":"661_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pcad.2021.09.001","volume":"68","author":"JA Laukkanen","year":"2021","unstructured":"Laukkanen JA, Savonen K, Hupin D, Ara\u00fajo CGS, Kunutsor SK. Cardiorespiratory optimal point during exercise testing and sudden cardiac death: a prospective cohort study. Prog Cardiovasc Dis. 2021;68:12\u20138. https:\/\/doi.org\/10.1016\/j.pcad.2021.09.001.","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"661_CR17","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/s0735-1097(96)00412-3","volume":"28","author":"R Baba","year":"1996","unstructured":"Baba R, Nagashima M, Goto M, Nagano Y, Yokota M, Tauchi N, et al. Oxygen uptake efficiency slope: a new index of cardiorespiratory functional reserve derived from the relation between oxygen uptake and minute ventilation during incremental exercise. J Am Coll Cardiol. 1996;28(6):1567\u201372. https:\/\/doi.org\/10.1016\/s0735-1097(96)00412-3.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"661_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/00149831-200308000-00008","volume":"10","author":"JY Tabet","year":"2003","unstructured":"Tabet JY, Beauvais F, Thabut G, Tarti\u00e8re JM, Logeart D, Cohen-Solal A. A critical appraisal of the prognostic value of the VE\/VCO2 slope in chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2003;10(4):267\u201372. https:\/\/doi.org\/10.1097\/00149831-200308000-00008.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"1","key":"661_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003.","journal-title":"J Am Soc Echocardiogr"},{"issue":"7","key":"661_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561\u2013632. https:\/\/doi.org\/10.1093\/eurheartj\/ehab395.","journal-title":"Eur Heart J"},{"key":"661_CR21","unstructured":"R-pRC: R: A language and environment for statistical computing. R Foundation for Statistical Computing. https:\/\/www.R-project.org\/. Accessed 22 October 2023"},{"issue":"1","key":"661_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/13506129.2021.1981281","volume":"29","author":"A Briasoulis","year":"2022","unstructured":"Briasoulis A, Stamatelopoulos K, Petropoulos I, Patras R, Theodorakakou F, Gavriatopoulou M, et al. Utilization and tolerance of beta-blockers among patients with AL amyloidosis. Amyloid. 2022;29(1):31\u20137. https:\/\/doi.org\/10.1080\/13506129.2021.1981281.","journal-title":"Amyloid"},{"issue":"11","key":"661_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.cardfail.2021.06.022","volume":"27","author":"T Dalia","year":"2021","unstructured":"Dalia T, Acharya P, Chan WC, Sauer AJ, Weidling R, Fritzlen J, et al. Prognostic role of cardiopulmonary exercise testing in wild-type transthyretin amyloid cardiomyopathy patients treated with tafamidis. J Card Fail. 2021;27(11):1285\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2021.06.022. (Low baseline peak oxygen consumption, oxygen pulse, circulatory power, and an exercise duration of less than 5.5 min had worse outcome for mortality, heart transplantation, and palliative inotrope therapy in patients with wild-type amyloidosis.).","journal-title":"J Card Fail"},{"issue":"4","key":"661_CR24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1536\/ihj.23-075","volume":"64","author":"Y Nakaya","year":"2023","unstructured":"Nakaya Y, Ogimoto A, Kitaoka H. Changes in exercise tolerance over time in patients with transthyretin amyloidosis cardiomyopathy treated with tafamidis. Int Heart J. 2023;64(4):647\u201353. https:\/\/doi.org\/10.1536\/ihj.23-075.","journal-title":"Int Heart J"},{"issue":"7","key":"661_CR25","doi-asserted-by":"publisher","first-page":"e008381","DOI":"10.1161\/circheartfailure.121.008381","volume":"15","author":"R Badr Eslam","year":"2022","unstructured":"Badr Eslam R, \u00d6zt\u00fcrk B, Rettl R, Capelle CDJ, Qin H, Binder C, et al. Impact of tafamidis and optimal background treatment on physical performance in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(7):e008381. https:\/\/doi.org\/10.1161\/circheartfailure.121.008381.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"661_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.amjcard.2019.03.035","volume":"124","author":"A Yunis","year":"2019","unstructured":"Yunis A, Doros G, Luptak I, Connors LH, Sam F. Use of ventilatory efficiency slope as a marker for increased mortality in wild-type transthyretin cardiac amyloidosis. Am J Cardiol. 2019;124(1):122\u201330. https:\/\/doi.org\/10.1016\/j.amjcard.2019.03.035.","journal-title":"Am J Cardiol"},{"issue":"8","key":"661_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jchf.2016.03.022","volume":"4","author":"R Malhotra","year":"2016","unstructured":"Malhotra R, Bakken K, D\u2019Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. JACC Heart Fail. 2016;4(8):607\u201316. https:\/\/doi.org\/10.1016\/j.jchf.2016.03.022.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"661_CR28","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/ejhf.899","volume":"19","author":"TS Clemmensen","year":"2017","unstructured":"Clemmensen TS, M\u00f8lgaard H, S\u00f6rensen J, Eiskjaer H, Andersen NF, Mellemkjaer S, et al. Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis. Eur J Heart Fail. 2017;19(11):1457\u201365. https:\/\/doi.org\/10.1002\/ejhf.899.","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"661_CR29","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1161\/circulationaha.121.054858","volume":"144","author":"MK Burrage","year":"2021","unstructured":"Burrage MK, Hundertmark M, Valkovi\u010d L, Watson WD, Rayner J, Sabharwal N, et al. Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction. Circulation. 2021;144(21):1664\u201378. https:\/\/doi.org\/10.1161\/circulationaha.121.054858.","journal-title":"Circulation"},{"issue":"38","key":"661_CR30","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237.","journal-title":"Eur Heart J"},{"issue":"3","key":"661_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11739-020-02474-1","volume":"16","author":"S Bartolini","year":"2021","unstructured":"Bartolini S, Baldasseroni S, Fattirolli F, Silverii MV, Piccioli L, Perfetto F, et al. Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients. Intern Emerg Med. 2021;16(3):653\u201360. https:\/\/doi.org\/10.1007\/s11739-020-02474-1.","journal-title":"Intern Emerg Med"},{"key":"661_CR32","doi-asserted-by":"publisher","unstructured":"Saito Y, Nakamura K, Ito H. Molecular mechanisms of cardiac amyloidosis. Int J Mol Sci. 2021;23(1). https:\/\/doi.org\/10.3390\/ijms23010025.","DOI":"10.3390\/ijms23010025"},{"issue":"21","key":"661_CR33","doi-asserted-by":"publisher","first-page":"e009974","DOI":"10.1161\/jaha.118.009974","volume":"7","author":"TS Clemmensen","year":"2018","unstructured":"Clemmensen TS, Soerensen J, Hansson NH, Tolbod LP, Harms HJ, Eiskj\u00e6r H, et al. Myocardial oxygen consumption and efficiency in patients with cardiac amyloidosis. J Am Heart Assoc. 2018;7(21):e009974. https:\/\/doi.org\/10.1161\/jaha.118.009974.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"661_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jchf.2017.10.014","volume":"6","author":"A Pandey","year":"2018","unstructured":"Pandey A, Khera R, Park B, Haykowsky M, Borlaug BA, Lewis GD, et al. Relative impairments in hemodynamic exercise reserve parameters in heart failure with preserved ejection fraction: a study-level pooled analysis. JACC Heart Fail. 2018;6(2):117\u201326. https:\/\/doi.org\/10.1016\/j.jchf.2017.10.014.","journal-title":"JACC Heart Fail"},{"key":"661_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ijcard.2022.10.009","volume":"370","author":"S Wernhart","year":"2023","unstructured":"Wernhart S, Papathanasiou M, Mahabadi AA, Rassaf T, Luedike P. Betablockers reduce oxygen pulse increase and performance in heart failure patients with preserved ejection fraction. Int J Cardiol. 2023;370:309\u201318. https:\/\/doi.org\/10.1016\/j.ijcard.2022.10.009.","journal-title":"Int J Cardiol"},{"key":"661_CR36","doi-asserted-by":"publisher","first-page":"108356","DOI":"10.1016\/j.pharmthera.2023.108356","volume":"243","author":"S Wernhart","year":"2023","unstructured":"Wernhart S, Papathanasiou M, Rassaf T, Luedike P. The controversial role of beta-blockers in heart failure with preserved ejection fraction. Pharmacol Ther. 2023;243:108356. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108356.","journal-title":"Pharmacol Ther"},{"key":"661_CR37","doi-asserted-by":"publisher","unstructured":"Jondeau G, Katz SD, Zohman L, Goldberger M, Mccarthy M, Bourdarias JP, et al. Active skeletal muscle mass and cardiopulmonary reserve. Failure to attain peak aerobic capacity during maximal bicycle exercise in patients with severe congestive heart failure. Circulation. 1992;86(5):1351\u20136. https:\/\/doi.org\/10.1161\/01.cir.86.5.1351.","DOI":"10.1161\/01.cir.86.5.1351"},{"issue":"18","key":"661_CR38","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1161\/01.cir.98.18.1886","volume":"98","author":"K Okita","year":"1998","unstructured":"Okita K, Yonezawa K, Nishijima H, Hanada A, Ohtsubo M, Kohya T, et al. Skeletal muscle metabolism limits exercise capacity in patients with chronic heart failure. Circulation. 1998;98(18):1886\u201391. https:\/\/doi.org\/10.1161\/01.cir.98.18.1886.","journal-title":"Circulation"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00661-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-024-00661-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00661-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:04:47Z","timestamp":1715591087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-024-00661-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1007\/s11897-024-00661-1","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"22 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PL received speaker honoraria and consulting fees from Astra Zeneca, Bayer, Pfizer, and Edwards Lifesciences, and research honoraria from Edwards Lifesciences. TR reports honoraria for lectures and advisory board activities for Bayer, AstraZeneca, Daiichi Sankyo, and Pfizer. TR is co-founder of Mycor, a start-up focussing on the development of algorithms to detect amyloidosis. None of these are related to the submitted manuscript. TR is a section editor for cardio-oncology for Current Heart Failure Reports. AC received consulting and\/or lecture fees from Amgen, Janssen, Pfizer, and Takeda and travel and congress participation grants from Janssen; none of these are related to the submitted manuscript. All other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Ethical approval was waived by the local Ethics Committee of University Duisburg-Essen in view of the retrospective nature of the study, and all the procedures being performed were part of the routine care.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}